Interview: Thierry Wurch on (Pre)Clinical Data for Allogenic CAR-T-Cell Approaches

InfoWeb Marketplace

Thursday, May 17, 2018Description :
Dr. Thierry Wurch, Director of External Studies in Immuno-oncology, Servier, summarizes his talk about the use of UCART19 against CD19-expressing hematological malignancies and the impressive clinical benefits leading to the marketing of the two first autologous CART-cell products Kymriah (Novartis) and Yescarta (Kite Gilead). Watch the entire lecture: More information about the Sartorius Research Xchange Forum on Trends and Challenges in Regenerative Medicine and Cell Therapy 2018:

Searches related toLaboratory equipment

Grouped quotes (0)